コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 sorder, bipolar disorder, schizophrenia, and attention-deficit/hyperactivity disorder).
2 rupted in many psychiatric disorders such as attention deficit hyperactivity disorder.
3 n associated with schizophrenia, autism, and attention deficit hyperactivity disorder.
4 ognitive symptoms of Alzheimer's disease and attention deficit hyperactivity disorder.
5 orable metabolic profile and a lower risk of attention deficit hyperactivity disorder.
6 ecreased susceptibility to schizophrenia and attention deficit hyperactivity disorder.
7 der, schizophrenia, Alzheimer's disease, and attention deficit hyperactivity disorder.
8 hostimulants, including the calming ones, in attention deficit hyperactivity disorder.
9 sociations with nonatopic conditions such as attention deficit hyperactivity disorder.
10 motivation, including obesity, addiction and attention deficit hyperactivity disorder.
11 ce use disorders, pathological gambling, and attention deficit hyperactivity disorder.
12 ents, but lower variability in patients with attention deficit hyperactivity disorder.
13 risk of bipolar disorder, schizophrenia and attention deficit-hyperactivity disorder.
14 several neuropsychiatric diseases, including attention deficit/hyperactivity disorder.
15 cal changes in the same set of patients with attention deficit/hyperactivity disorder.
16 erapeutic effects of oral methylphenidate in attention deficit/hyperactivity disorder.
17 renia, bipolar disorder, autism, anxiety and attention deficit/hyperactivity disorder.
18 lopmental disorders, particularly autism and attention-deficit hyperactivity disorder.
19 its underlying psychiatric disorders such as attention-deficit hyperactivity disorder.
20 on models or after the exclusion of comorbid attention-deficit/hyperactivity disorder.
21 ntinuous Performance Test and diagnosis with attention-deficit/hyperactivity disorder.
22 nts are highly effective in the treatment of attention-deficit/hyperactivity disorder.
23 istent with previous findings in adults with attention-deficit/hyperactivity disorder.
24 psychiatric condition or substance abuse and attention-deficit/hyperactivity disorder.
25 radrenergic reuptake inhibitor used to treat attention-deficit/hyperactivity disorder.
26 consistent with prior studies in adults with attention-deficit/hyperactivity disorder.
27 cluding schizophrenia, bipolar disorder, and attention-deficit/hyperactivity disorder.
28 estational age, autism spectrum disorder, or attention-deficit/hyperactivity disorder.
29 analysis, of whom 25 (4.8%) met criteria for attention-deficit/hyperactivity disorder.
30 olar disorder, major depressive disorder, or attention-deficit/hyperactivity disorder.
31 [0.2%]; adjusted RR, 4.3; 95% CI, 2.3-8.2), attention-deficit/hyperactivity disorder (189 cases [5.3
33 ar bipolar disorder (94.2 [1.69]; P = .004), attention-deficit/hyperactivity disorder (96.3 [0.91]; P
34 omoxetine are used in the pharmacotherapy of attention deficit hyperactivity disorder, a common condi
36 al deficits, we also tested 21 children with attention deficit (hyperactivity) disorder [AD(H)D].
37 g been recognized that many individuals with attention deficit hyperactivity disorder (ADHD) also hav
40 son's disease (PD) as well as treatments for attention deficit hyperactivity disorder (ADHD) and depr
41 ociated with autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD) and schi
42 and to neuropsychiatric disorders including attention deficit hyperactivity disorder (ADHD) and schi
43 or (GRM) GFIN, previously observed to impact attention deficit hyperactivity disorder (ADHD) and schi
44 number of psychiatric conditions, including attention deficit hyperactivity disorder (ADHD) and subs
46 esses tied to the adult outcome of childhood attention deficit hyperactivity disorder (ADHD) could gu
54 d treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD) is uncle
56 olescents and young adults without childhood attention deficit hyperactivity disorder (ADHD) often pr
57 This study examined the effects of childhood attention deficit hyperactivity disorder (ADHD) symptoms
58 tism, bipolar disorder, major depression and attention deficit hyperactivity disorder (ADHD) using ge
60 speech impairment, variable expressivity of attention deficit hyperactivity disorder (ADHD), and mot
61 ed executive inhibition is a core deficit of attention deficit hyperactivity disorder (ADHD), which i
62 moderate the effect of stress on severity of attention deficit hyperactivity disorder (ADHD), with st
63 s to excess mortality among individuals with attention deficit hyperactivity disorder (ADHD), yet ass
64 4, and illustrate a use case of HaploReg for attention deficit hyperactivity disorder (ADHD)-associat
75 ed for children who have been diagnosed with attention deficit hyperactivity disorder (ADHD); however
76 mental exposure to PBDEs and intelligence or Attention Deficit/Hyperactivity Disorder (ADHD) and atte
77 gression is widely observed in children with attention deficit/hyperactivity disorder (ADHD) and has
78 ental report of learning disability (LD) and attention deficit/hyperactivity disorder (ADHD) in child
79 renatal exposure to PFASs is associated with attention deficit/hyperactivity disorder (ADHD) or child
80 tal carbon attributed to traffic (ECAT), and attention deficit/hyperactivity disorder (ADHD) symptoms
81 features, including intellectual disability, attention deficit/hyperactivity disorder (ADHD), and aut
82 um PCB levels in infancy are associated with attention deficit/hyperactivity disorder (ADHD)-related
85 ndings are mixed on the relationship between attention-deficit hyperactivity disorder (ADHD) and youn
87 ral studies have questioned the stability of attention-deficit hyperactivity disorder (ADHD) from chi
94 9A is located close to a previously reported attention-deficit hyperactivity disorder (ADHD) linkage
98 tine, drugs widely used for the treatment of attention-deficit hyperactivity disorder (ADHD), suppres
99 n two male siblings who share a diagnosis of attention-deficit hyperactivity disorder (ADHD), with ot
103 Brain Imaging Data Exchange (ABIDE) and the Attention-Deficit Hyperactivity Disorder (ADHD-200) data
104 elations were found between extraversion and attention-deficit-hyperactivity disorder (ADHD) and betw
106 ofiles in autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) - preval
110 compared and contrasted with trajectories in attention-deficit/hyperactivity disorder (ADHD) and chil
111 dication has long been effective in treating attention-deficit/hyperactivity disorder (ADHD) and is c
113 lphenidate (MPH) is used clinically to treat attention-deficit/hyperactivity disorder (ADHD) and off-
118 earch has demonstrated that individuals with attention-deficit/hyperactivity disorder (ADHD) are more
119 sses underlying persistence and remission of attention-deficit/hyperactivity disorder (ADHD) are poor
123 gical and hemodynamic activity is altered in attention-deficit/hyperactivity disorder (ADHD) during t
131 ic resonance imaging (fMRI) studies of adult attention-deficit/hyperactivity disorder (ADHD) have rev
132 Previous neuroimaging investigations in attention-deficit/hyperactivity disorder (ADHD) have sep
133 volumetric differences were associated with attention-deficit/hyperactivity disorder (ADHD) in a rec
134 ys been a key criterion for the diagnosis of attention-deficit/hyperactivity disorder (ADHD) in adult
156 p between autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) is incre
164 A neurobiological-based classification of attention-deficit/hyperactivity disorder (ADHD) subtypes
165 based on network strength at rest predicted attention-deficit/hyperactivity disorder (ADHD) symptoms
166 between the attenuation of VLF EEG power and Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms
167 mphetamine and cannabis co-use, craving, and attention-deficit/hyperactivity disorder (ADHD) symptoms
169 ssociated with a categorical ASD diagnosis); attention-deficit/hyperactivity disorder (ADHD) traits (
170 when obsessive-compulsive disorder (OCD) and attention-deficit/hyperactivity disorder (ADHD) were exc
171 elating maternal smoking during pregnancy to attention-deficit/hyperactivity disorder (ADHD) without
172 modeling complex brain disorders, including attention-deficit/hyperactivity disorder (ADHD), aggress
173 receptor (NNR) system has been implicated in attention-deficit/hyperactivity disorder (ADHD), and nic
174 to investigate the genetic susceptibility of Attention-Deficit/Hyperactivity Disorder (ADHD), but wit
175 phenidate hydrochloride for the treatment of attention-deficit/hyperactivity disorder (ADHD), little
176 ivity, a multifaceted behavioral hallmark of attention-deficit/hyperactivity disorder (ADHD), strongl
177 er to better understand the underpinnings of attention-deficit/hyperactivity disorder (ADHD), we targ
179 This study extends the literature regarding attention-deficit/hyperactivity disorder (ADHD)-related
196 riants with long repeats have been linked to attention-deficit/hyperactivity disorder (ADHD); however
199 al-reported symptoms of depression, anxiety, attention/deficit hyperactivity disorder (ADHD), opposit
201 toms were more likely to have a diagnosis of attention-deficit/hyperactivity disorder (adjusted odds
202 he proportion who were clinically at risk of attention deficit hyperactivity disorders after Bonferro
203 ers, including excessive daytime sleepiness, attention deficit hyperactivity disorder, Alzheimer dise
204 (mood and anxiety), behavioral disturbance (attention deficit hyperactivity disorder and conduct dis
205 been implicated in mental disorders, such as attention deficit-hyperactivity disorder and schizophren
208 ole in neuropsychiatric disorders, including attention-deficit hyperactivity disorder and drug addict
209 orders, including schizophrenia, depression, attention-deficit hyperactivity disorder and substance a
211 disorders, including infantile parkinsonism, attention-deficit/hyperactivity disorder and autism spec
212 s characterized by high impulsivity, such as attention-deficit/hyperactivity disorder and bipolar dis
214 opment of novel pharmacologic treatments for attention-deficit/hyperactivity disorder and other condi
215 r across sex, after excluding relatives with attention-deficit/hyperactivity disorder and probands wi
216 l relevance to the etiology and treatment of attention-deficit/hyperactivity disorder and related dis
217 hiatric disorders listed in DSM-5, including attention-deficit/hyperactivity disorder and substance u
218 e risk of suicidal behavior in patients with attention-deficit/hyperactivity disorder and suggests th
219 rgent results were obtained for the level of attention-deficit/hyperactivity disorder and the influen
220 disorder and suggests that individuals with attention-deficit/hyperactivity disorder and their famil
222 xiety, disruptive mood dysregulation, and/or attention-deficit/hyperactivity disorders and 22 healthy
223 bsessive-compulsive disorder and behaviours, attention deficit hyperactivity disorder, and autistic s
224 adolescent psychopathology, such as anxiety, attention deficit hyperactivity disorder, and substance
225 opmental disorders, including schizophrenia, attention deficit/hyperactivity disorder, and autism spe
226 pes of care and inpatient well-newborn care, attention-deficit/hyperactivity disorder, and asthma amo
227 ial behavior, posttraumatic stress disorder, attention-deficit/hyperactivity disorder, and conduct pr
228 ral psychiatric diseases, such as addiction, attention-deficit/hyperactivity disorder, and schizophre
229 al psychiatric disorders, such as addiction, attention-deficit/hyperactivity disorder, and schizophre
230 rodevelopmental disorders, including autism, attention-deficit/hyperactivity disorder, and schizophre
231 sease, schizophrenia, autism, depression and attention deficit hyperactivity disorder, as well as age
232 e a family of neurodevelopmental phenotypes (attention deficit hyperactivity disorder, autism spectru
233 neurologic disorders in offspring, including attention deficit/hyperactivity disorder, autism, and sc
234 ts with a psychiatric diagnosis of interest (attention-deficit/hyperactivity disorder, autism spectru
236 ur candidates under clinical development for attention deficit hyperactivity disorder, binge eating d
237 sensory gating, and social behavior and that attention deficit hyperactivity disorder, bipolar disord
238 lycerides, type 2 diabetes, waist-hip ratio, attention deficit hyperactivity disorder, bipolar disord
239 associations of smoking with drug and AUDs, attention-deficit hyperactivity disorder, bipolar disord
240 ase guanfacine is approved for children with attention deficit hyperactivity disorder but not well st
241 ed vs 5.46% of unexposed were diagnosed with attention-deficit/hyperactivity disorder by age 15 years
242 he study of monozygotic twins discordant for attention deficit hyperactivity disorder can elucidate m
243 o diseases such as schizophrenia, autism and attention deficit/hyperactivity disorder, CNVs do not ap
244 sits in 2007-2010 but represented 55.9% when attention-deficit/hyperactivity disorder codes were excl
245 but high variability in patients with autism/attention deficit hyperactivity disorder, compared with
247 before age 2 nearly doubles the risk for an attention-deficit hyperactivity disorder diagnosis by ag
248 ited understanding of why many children with attention deficit hyperactivity disorder do not outgrow
249 e drugs, antihypertensive drugs, sleep aids, attention-deficit/hyperactivity disorder drugs, and anti
250 for the treatment of insomnia [sleep aids], attention-deficit/hyperactivity disorder drugs, antidepr
251 evelopmental disabilities, including autism, attention-deficit hyperactivity disorder, dyslexia, and
252 s is associated with preschool-aged onset of attention-deficit/hyperactivity disorder; early exposure
253 between them and schizophrenia, depression, attention-deficit/hyperactivity disorder, eating disorde
254 dividuals with major depressive disorder and attention-deficit hyperactivity disorder from their cont
255 a clinical measure of attention--symptoms of attention deficit hyperactivity disorder--from resting-s
257 g state studies examining the brain basis of attention deficit hyperactivity disorder have not distin
258 hazard ratio [HR], 2.02 [95% CI, 1.80-2.26]; attention-deficit/hyperactivity disorder HR, 2.21 [95% C
259 azard ratio [HR] = 3.45; 95% CI, 1.62-7.33), attention-deficit/hyperactivity disorder (HR = 13.13; 95
260 disorder (HR, 0.83 [95% CI, 0.62-1.13]), or attention-deficit/hyperactivity disorder (HR, 0.99 [95%
261 formly characterized as having or not having attention deficit hyperactivity disorder in childhood an
262 disorders such as schizophrenia, autism, and attention-deficit/hyperactivity disorder in humans.
263 al diagnosis of autism spectrum disorder and attention-deficit/hyperactivity disorder in offspring.
264 tipsychotics, the most common diagnoses were attention-deficit/hyperactivity disorder in younger chil
266 nidate, a common and effective treatment for attention-deficit/hyperactivity disorder, in healthy adu
270 eneral anesthesia exposure early in life and attention deficit hyperactivity disorder, language proce
271 on between the persistence and remittance of attention deficit hyperactivity disorder may provide a f
272 nge of neuropsychiatric illnesses, including attention deficit hyperactivity disorder, mood disorders
274 h schizophrenia (N=3540), autism (N=16 146), attention-deficit/hyperactivity disorder (N=18 726) and
275 lphenidate (MPH), a first-line treatment for attention deficit hyperactivity disorder, on D2/3 recept
276 ed with neurotransmitter dysregulation, e.g. attention deficit hyperactivity disorder or Alzheimer's
277 While there was no association with comorbid attention-deficit/hyperactivity disorder or IQ, age rang
279 d 3.3-fold (95% CI: 1.4, 7.7) higher odds of attention deficit/hyperactivity disorder problems compar
281 gnaling in humans associated with addiction, attention-deficit/ hyperactivity disorder, schizophrenia
282 disorders (intellectual disability, autism, attention-deficit/hyperactivity disorder, schizophrenia,
283 ed for substance abuse, Parkinson's disease, attention-deficit/hyperactivity disorder, schizophrenia,
284 the genetic signature of DD overlapped with attention-deficit/hyperactivity disorder, schizophrenia,
285 nxiety disorders, autism spectrum disorders, attention deficit/hyperactivity disorder, severe learnin
286 tric (psychotic or bipolar disorder, autism, attention-deficit/hyperactivity disorder, suicide attemp
288 tion (outlier magnitude) relates to specific attention-deficit/hyperactivity disorder symptoms (hyper
289 externalizing behavioral problems, including attention-deficit/hyperactivity disorder symptoms and co
290 ediate factors (child executive function and attention-deficit/hyperactivity disorder symptoms) and c
291 ants contributes to slower processing speed, attention-deficit/hyperactivity disorder symptoms, and e
292 ng nigro-striatal dopaminergic mechanisms of attention deficit/hyperactivity disorder that extends in
293 of suicidal behavior among individuals with attention-deficit/hyperactivity disorder, the developmen
298 0.05 and P </= 0.01) with schizophrenia and attention deficit hyperactivity disorder were also nomin
299 s between ICN dysmaturation and diagnosis of attention-deficit/hyperactivity disorder were identified
300 portant update and suggest that treatment of attention-deficit/hyperactivity disorder with stimulant
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。